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A B S T R A C T
Recent genome-wide association studies have identiﬁed various dyslipidemia-related genetic variants. However,
most studies were conducted in a cross-sectional manner. We thus performed longitudinal exome-wide asso-
ciation studies of dyslipidemia in a Japanese population. We used ~244,000 genetic variants and clinical data of
6022 Japanese individuals who had undergone annual health checkups for several years. After quality control,
the association of dyslipidemia-related phenotypes with 24,691 single nucleotide polymorphisms (SNPs) was
tested using the generalized estimating equation model. In total, 82 SNPs were signiﬁcantly (P < 2.03×10−6)
associated with dyslipidemia phenotypes. Of these SNPs, four (rs74416240 of TCHP, rs925368 of GIT2,
rs7969300 of ATXN2, and rs12231744 of NAA25) and two (rs34902660 of SLC17A3 and rs1042127 of CDSN)
were identiﬁed as novel genetic determinants of hypo-HDL- and hyper-LDL-cholesterolemia, respectively. A
replication study using the cross-sectional data of 8310 Japanese individuals showed the association of the six
identiﬁed SNPs with dyslipidemia-related traits.
1. Introduction
Dyslipidemia is deﬁned as the abnormal serum concentrations of
triglycerides, low-density lipoprotein (LDL)-cholesterol, and high-den-
sity lipoprotein (HDL)-cholesterol; hypertriglyceridemia and hyper-
LDL-cholesterolemia indicate the increased serum concentrations of
triglycerides and LDL-cholesterol, respectively, while hypo-HDL-cho-
lesterolemia indicates a decreased serum concentration of HDL-cho-
lesterol. The National Health and Nutrition Examination Survey data
has reported a high prevalence of dyslipidemia (53%) in 2003–2006
among adults in the United States [1]. Meanwhile the Ministry of
Health, Labour and Welfare has reported that 21.8% of the Japanese
adults were suspected to have dyslipidemia in 2016 [2]. Dyslipidemia
can be a risk factor for various disorders, including coronary heart
disease and ischemic stroke [3–5]. Therefore, the investigation of
susceptibility genes for dyslipidemia is crucial for personalized disease
prevention.
Previous studies have identiﬁed a number of genetic variants af-
fecting the serum concentrations of triglycerides, LDL-cholesterol, and
HDL-cholesterol. A large-scale meta-analysis of genome-wide associa-
tion studies (GWASs) of plasma lipids has identiﬁed 95 loci related to
lipid traits, and 59 of the identiﬁed loci were newly reported in the
study [6]. Another large-scale meta-analysis conducted to further assess
the genetic association of these loci with plasma lipid phenotypes, has
identiﬁed candidate genetic variants in 21 previously unreported genes
[7]. Furthermore, a two-stage association study for LDL-cholesterol
focusing upon rare or low-frequency variants in protein-coding regions
has revealed signiﬁcant relations between LDL-cholesterol and addi-
tional unreported genetic variants [8]. Although previous studies have
identiﬁed common genetic variants that confer susceptibility to
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dyslipidemia across various ethnic groups, the interethnic diﬀerences in
the disease susceptibility loci have been observed [9, 10]. Therefore, it
is possible that novel susceptibility loci for dyslipidemia remain to be
identiﬁed deﬁnitively in Japanese.
Conventional GWASs have been conducted using a cross-sectional
study design that commonly measures traits at a single point in time.
Therefore, subjects who are likely to be aﬀected by dyslipidemia in the
future may be regarded as controls at the time of data collection. To
address this issue, we traced the blood lipid proﬁles of 6022 Japanese
individuals who had undergone annual health checkups over several
years. To identify dyslipidemia-related genetic variants, we performed
longitudinal exome-wide association studies of the prevalence of hy-
pertriglyceridemia, hyper-LDL-cholesterolemia, or hypo-HDL-choles-
terolemia as well as the serum concentrations of triglycerides, LDL-
cholesterol, or HDL-cholesterol.
2. Results
2.1. Characteristics of subjects in the discovery cohort
We measured the blood lipid proﬁles of 6022 community-dwelling
individuals who visited the Health Care Center at Inabe General
Hospital, Inabe City, Japan, for an annual health checkup from April
2003 to March 2014 (mean follow-up period, 5 years). We refer to this
cohort as “discovery cohort.” The characteristics of the 6022 subjects in
the discovery cohort concerning the longitudinal data are summarized
in Table 1. The prevalence of dyslipidemia based on longitudinal data
was higher in males than in females; the proportion of males was
73.5%, 83.9%, and 55.6% among subjects with hypertriglyceridemia,
hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia, respec-
tively. Compared with the controls, the prevalence of other complex
disorders (hypertension, type 2 diabetes mellitus, chronic kidney dis-
ease, and hyperuricemia) was higher in subjects with dyslipidemia.
Most physiological or clinical parameters examined [age, weight, body
mass index (BMI), waist circumference, systolic and diastolic blood
pressure, fasting plasma glucose level, blood hemoglobin A1c content,
and serum concentrations of creatinine and uric acid] were higher,
whereas estimated glomerular ﬁltration rate was lower in the subjects
with dyslipidemia than in the controls.
2.2. Longitudinal exome-wide association study for hypertriglyceridemia
In our longitudinal exome-wide association studies of the 6022
subjects in the discovery cohort, the relations of 24,691 single nu-
cleotide polymorphisms (SNPs) were tested for three inheritance
models with six dyslipidemia-related parameters (hypertriglyceridemia;
hypo-HDL-cholesterolemia; hyper-LDL-cholesterolemia; and serum
concentrations of triglycerides, HDL-cholesterol, or LDL-cholesterol)
using the generalized estimating equation (GEE) models after adjusting
for age, sex, BMI, and smoking status. SNPs with statistical signiﬁcance
(P < 2.03× 10−6) were further ﬁltered out by the threshold of ap-
proxdf (a scale of small eﬀective sample size) of> 30. The study design
and results of the longitudinal exome-wide association studies are
shown in Fig. 1 and Fig. 2 or Supplementary Tables S1–S3, respectively.
In the longitudinal exome-wide association studies for hyper-
triglyceridemia, 26 diﬀerent SNPs were signiﬁcantly
(P < 2.03× 10−6, approxdf> 30) associated with the prevalence of
hypertriglyceridemia in the three inheritance models, whereas another
set of 26 SNPs was signiﬁcantly associated with the serum triglyceride
concentration (Fig. 2 and Supplementary Tables S1–S3). Between these
two sets of 26 SNPs, 22 were overlapped. Among 30 SNPs identiﬁed, 28
had been previously reported to be associated with dyslipidemia-re-
lated phenotypes according to Genome-Wide Repository of Associations
Between SNPs and Phenotypes (GRASP), GWAS Catalogue, and Dis-
GeNET databases. The remaining two SNPs were in a linkage dis-
equilibrium (LD) with SNPs that have been reported to be associated
with dyslipidemia phenotypes (r2 > 0.85), according to LDproxy
analysis, an LDlink web-based application, for JPT (Japanese in Tokyo,
Japan) from the 1000 Genomes Project. Hence, these two SNPs were
not considered as novel susceptibility loci for hypertriglyceridemia.
2.3. Longitudinal exome-wide association study for hypo-HDL-
cholesterolemia
The GEE models with adjustments for age, sex, BMI, and smoking
status revealed 21 SNPs signiﬁcantly (P < 2.03×10−6, approxdf>
30) associated with the prevalence of hypo-HDL-cholesterolemia in the
dominant and additive models (Fig. 2 and Supplementary Tables
S1–S3). In the longitudinal exome-wide association studies of serum
HDL-cholesterol concentration, 45 SNPs were signiﬁcantly associated in
the three inheritance models. Between the two sets of 21 and 45 SNPs,
20 were overlapped. Thus, 46 SNPs were associated with HDL-choles-
terol-related phenotypes in the discovery cohort.
Of the 46 SNPs, 8 had not been identiﬁed as signiﬁcantly associated
with dyslipidemia-related phenotypes according to the three databases.
LDs between the eight SNPs and previously identiﬁed SNPs in JPT from
the 1000 Genomes Project were surveyed using LDproxy and GRASP
database (see Materials and methods). An r2 value was adopted as a
marker to estimate the strength of LD because r2 is directly linked to
statistical power for detecting an association between the prevalence of
disease and the allele frequencies of the target and adjacent SNPs [11].
On the basis of the previous studies [11, 12], an r2 of> 0.5 was con-
sidered to be a signiﬁcant LD. The analysis using LDproxy and GRASP
indicated that four of the eight SNPs were in LD (r2 > 0.5) with SNPs
previously identiﬁed associated with dyslipidemia. Thus, these SNPs
were not considered as novel susceptibility loci. Consequently, the re-
maining four SNPs [rs74416240 of TCHP (P=6.2× 10−9, ap-
proxdf= 76), rs925368 of GIT2 (P=6.4×10−9, approxdf= 69),
rs7969300 of ATXN2 (P=7.0× 10−8, approxdf= 266–466), and
rs12231744 of NAA25 (P=3.1×10−7, approxdf= 283–369)] were
identiﬁed as novel genetic determinants of hypo-HDL-cholesterolemia.
These SNPs are closely located in the chromosomal region
12q24.11–q24.13 (Fig. 3).
In the present study, LD was observed between rs74416240 and
rs925368 (r2=0.94) as well as between rs7969300 and rs12231744
(r2=0.68) (Fig. 3), suggesting that the eﬀects of these SNPs on serum
HDL-cholesterol concentration were not independent. Furthermore, r2
values between the four identiﬁed and some adjacent SNPs were ~0.3,
indicating a weak LD among these SNPs. Thus, the association of the
four identiﬁed SNPs with dyslipidemia might be aﬀected to a certain
extent by other adjacent SNPs that confer susceptibility to dyslipidemia.
The association between the four identiﬁed SNPs and hypo-HDL-cho-
lesterolemia-related phenotypes should be carefully interpreted, and
further functional analyses are required to verify the association.
2.4. Longitudinal exome-wide association study for hyper-LDL-
cholesterolemia
Our longitudinal exome-wide association studies revealed that two
SNPs were signiﬁcantly (P < 2.03×10−6, approxdf> 30) associated
with the prevalence of hyper-LDL-cholesterolemia in the dominant and
additive models. Furthermore, 24 SNPs were signiﬁcantly associated
with serum LDL-cholesterol concentration (Fig. 2 and Supplementary
Tables S1–S3). Of the 26 associated SNPs, rs34902660 of SLC17A3 was
associated with both the prevalence of hyper-LDL-cholesterolemia and
the serum concentration of LDL-cholesterol. In total, 25 SNPs were
signiﬁcantly associated with phenotypes related to LDL-cholesterol.
According to the analysis using LDproxy and GRASP database (see
above), two [rs34902660 of SLC17A3 (P=1.8×10−7 to 1.2×10−6,
approxdf= 31–34) and rs1042127 of CDSN (P=2.4× 10−7 to
1.3×10−6, approxdf= 162)] of the 25 SNPs were identiﬁed as novel
susceptibility loci for hyper-LDL-cholesterolemia.
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In the discovery cohort, r2 values between the two identiﬁed SNPs
and some adjacent SNPs were ~0.4 (Fig. 4). The rs34902660 of
SLC17A3 showed a weak LD (r2= 0.41) with rs9267546 previously
identiﬁed to be associated with serum triglyceride concentration. Thus,
the association of rs34902660 with dyslipidemia might be aﬀected to a
certain extent by rs9267546. The association should be carefully
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HWE p > 0.001 etc.
GEE model
Fig. 1. Study ﬂow chart. An approxdf is a scale of small
eﬀective sample size: approxdf=2×MAF×Nindep,
where Nindep is the sum of the estimated number of
independent observations per person. GEE, generalized
estimating equation. GWAS, genome-wide association
study. HDL, high density lipoprotein. HWE,
Hardy–Weinberg equilibrium. LDL, low density lipo-
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Fig. 2. SNPs showing signiﬁcant association with dyslipidemia. The association was tested by the generalized estimating equation model with adjustments for age,
sex, BMI, and smoking status in the (A) dominant, (B) additive, and (C) recessive inheritance models. The analyses independently tested the association between SNPs
and six clinical parameters: prevalence of hypertriglyceridemia, hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia or serum concentrations of triglycerides,
HDL-cholesterol, and LDL-cholesterol. After employing Bonferroni's correction, P < 2.03× 10−6 was considered statistically signiﬁcant. HDL, high density lipo-
protein. LDL, low density lipoprotein.
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interpreted, and further functional analyses are warranted to verify the
association.
2.5. Replication studies for candidate SNPs associated with dyslipidemia
The association of the six candidate SNPs identiﬁed in our long-
itudinal exome-wide association studies with the six dyslipidemia-re-
lated traits was examined using the cross-sectional data of 8310
Japanese subjects (see Materials and methods) in the replication cohort
(Table 2). In this replication study, all six candidate SNPs were asso-
ciated (P < .05) with at least three of the six phenotypes examined: the
rs1042127 of CDSN was associated with the serum concentrations of
triglycerides and HDL-cholesterol and the prevalence of hypo-HDL-
cholesterolemia although this SNP was related to serum LDL-cholesterol
concertation in the discovery cohort.
We also examined the association of the six candidate SNPs with the
dyslipidemia-related traits using cross-sectional data of all Japanese
subjects (14,332 subjects) in the combined cohort of discovery and
replication cohorts (Table 2): we refer to this cohort as “entire cohort.”
Here, in the discovery cohort, cross-sectional data of 6022 subjects in
the latest year were used. In the entire cohort, the association of the
candidate SNPs with dyslipidemia-related phenotypes showed good
agreement with that observed in the discovery cohort: four
(rs74416240, rs925368, rs7969300, and rs12231744) and two
(rs34902660 and rs1042127) SNPs were signiﬁcantly [P < .008 (0.05/
6 SNPs)] associated with serum concentrations of HDL- and LDL-cho-
lesterol, respectively.
Additionally, the association of the candidate SNPs detected in the
discovery cohort with dyslipidemia phenotypes was examined using
large datasets from four previous GWASs [13–16], data for which are
deposited in GRASP database (Supplementary Table S4). Information
regarding P-values was available for rs1042127 of CDSN but not for the
other ﬁve SNPs because minor allele frequencies (MAFs) of these SNPs
were < 0.3% in European populations on the basis of the allele fre-
quency data of the 1000 Genomes Project (Table 3). In agreement with
the results of our replication study, rs1042127 was not associated with
serum LDL cholesterol concentration in the 4 GWAS datasets, but was
associated with serum HDL cholesterol concentration in the studies of
Teslovich et al. [13] (P-value= .032) and Willer et al. [16] (P-
value= 3.5× 10−4) (Supplementary Table S4).
2.6. Comparisons of quantitative data among subjects with diﬀerent
genotypes of the six identiﬁed SNPs in the discovery cohort
Based on the blood lipid proﬁles of the subjects in the latest year,
the quantitative values of dyslipidemia-related phenotypes were com-
pared among diﬀerent genotypes of the six identiﬁed SNPs in the dis-
covery cohort (Table 4). In comparisons of the four candidate SNPs
associated with hypo-HDL-cholesterolemia, serum HDL-cholesterol
concentration was signiﬁcantly (P < .008, by one-way analysis of
variance) lower in the major alleles [A (rs925368), T (rs7969300), and
C (rs12231744)] than in the corresponding minor alleles (G, C, and T).
In contrast, serum HDL-cholesterol concentration was signiﬁcantly
lower in the minor allele (A) of rs74416240 than in the major allele (G).
These results suggest that the major alleles of rs925368, rs7969300,
and rs12231744 and the minor allele of rs74416240 may be risk factors
for hypo-HDL-cholesterolemia. Serum LDL-cholesterol concentrations
were signiﬁcantly higher in subjects with the minor alleles of two
candidate SNPs [A (rs34902660) and G (rs1042127)] associated with


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 3. Linkage disequilibrium map of 43 biallelic sites in a ~3.1Mb genomic region at 12q24.11–q24.13 in the discovery cohort. The number in a diamond
represents r2 value (×100). The SNPs with a minor allele frequency of< 0.01 were excluded from the analysis. The dyslipidemia-related SNPs detected in the present
and previous studies are indicated in blue. The novel dyslipidemia-related SNPs detected in the present study are indicated in red.
Y. Yasukochi et al. Genomics 111 (2019) 520–533
524
and T), suggesting that these minor alleles may be risk factors for hyper-
LDL-cholesterolemia.
We examined the relation of each candidate SNP to serum con-
centrations of HDL-cholesterol or LDL-cholesterol in the replication
cohort (Table 5). The serum concentrations of HDL-cholesterol were
signiﬁcantly (P < .008) diﬀerent among genotypes in the four SNPs
associated with hypo-HDL-cholesterolemia, whereas the two SNPs
(rs34902660 and rs1042127) associated with hyper-LDL-cholester-
olemia were not signiﬁcantly related to the serum LDL-cholesterol le-
vels. This discrepancy may be attributable to the eﬀect of medical
treatment, given that subjects in the replication study were recruited
from individuals either who visited outpatient clinics of or were ad-
mitted to participating hospitals. We have thus examined the relation of
six SNPs to the serum levels of HDL-cholesterol or LDL-cholesterol in
the entire cohort. The serum LDL- or HDL-cholesterol levels were sig-
niﬁcantly diﬀerent among genotypes in all the six SNPs (Table 5). The
relations of six SNPs to serum LDL- or HDL-cholesterol levels in dis-
covery and replication cohorts have been shown as box-plots in Figs. 5
and 6, respectively.
3. Discussion
In our longitudinal exome-wide association studies for dyslipi-
demia-related traits, 82 SNPs were signiﬁcantly associated with at least
one of the six phenotypes. Of the 82 SNPs, four (rs74416240 of TCHP,
rs925368 of GIT2, rs7969300 of ATXN2, and rs12231744 of NAA25)
and two (rs34902660 of SLC17A3 and rs1042127 of CDSN) were
identiﬁed as novel susceptibility loci for hypo-HDL-cholesterolemia and
hyper-LDL-cholesterolemia, respectively. The association of these SNPs
with dyslipidemia-related phenotypes was replicated using the cross-
sectional data of 8310 Japanese individuals as well as 14,332 in-
dividuals in the entire cohort. The discovery and replication cohorts are
comprised of only Japanese individuals, and ﬁve of six novel suscept-
ibility loci identiﬁed in the present study were monomorphic or rare
variants in European populations. Therefore, our ﬁndings may not be
generalizable to other racial or ethnic groups such as European
Americans.
In the discovery cohort, rs74416240 of TCHP and rs925368 of GIT2
were in LD (r2=0.94). These SNPs were signiﬁcantly associated with
serum HDL-cholesterol concentration. A previous GWAS has shown the
association (P=7.0× 10−6) between another SNP, rs2292354 of
GIT2, and serum HDL-cholesterol concentrations in Asian Indian males
[17]. Thus, GIT2 might be more important for lipid metabolisms than
TCHP although it is diﬃcult to distinguish which SNP is responsible for
the lipid metabolisms. GIT2 is a member of G-protein-coupled receptor-
kinase-interacting proteins involved in diverse cellular processes, such
as the regulation of membrane traﬃcking between the plasma mem-
brane and endosomes [18]. According to The Human Protein Atlas
(http://www.proteinatlas.org/), GIT2 is ubiquitously expressed in var-
ious organs and tissues. Given that molecules related to lipid metabo-
lism are involved in membrane transport processes [19], GIT2 might





























































































































































































































































































































Block 1 (363 kb) Block 2 (437 kb)
6p21.32—p22.2
Fig. 4. Linkage disequilibrium map of 21 biallelic sites in a ~6.2Mb genomic region at 6p21.32–p22.2 in the discovery cohort. The number in a diamond represents
r2 value (×100). The SNPs with a minor allele frequency of< 0.01 were excluded from the analysis. The dyslipidemia-associated SNPs detected in the present and
previous studies are shown in blue. The novel dyslipidemia-related SNPs detected in the present study are shown in red.
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functional analyses are required to elucidate the role of GIT2 in the
molecular mechanisms underlying hypo-HDL-cholesterolemia. Allele
frequency data from the 1000 Genomes Project indicates that the SNPs
in GIT2 and TCHP may be susceptible loci for dyslipidemia speciﬁc to
East Asian populations.
In the discovery cohort, rs12231744 of NAA25 exhibited moderate
LD with rs7969300 of ATXN2 (r2=0.68). The rs12231744 (T→ C,
K876R) in the NAA25 and rs7969300 (C→ T, S248N) in ATXN2 were
signiﬁcantly associated with serum HDL-cholesterol concentration. The
protein encoded by NAA25 is a component of the N-terminal acetyl-
transferase B complex and is involved in cell cycle progression [20],
while ATXN2 protein is involved mRNA translation regulation [21].
These proteins are expressed in various organs and tissues (The Human
Protein Atlas). The association of other SNPs in NAA25 and ATXN2 with
the serum concentrations of LDL-cholesterol or total cholesterol has
been determined in a previous GWAS of individuals with European
ancestry [13]. Although the functional relevance of the candidate SNPs
to serum HDL-cholesterol concentration remains unclear, the associa-
tion of NAA25 or ATXN2 might be attributable to the eﬀect on ﬂuc-
tuations in serum HDL-cholesterol levels in Japanese populations.
The rs34902660 of SLC17A3 was signiﬁcantly associated with
serum LDL-cholesterol concentration in the present study. The protein
encoded by SLC17A3 is an eﬄux transporter of intracellular urate and
organic anions from the blood into the renal tubule cells. SLC17A3 is
expressed in the liver and kidney (The Human Protein Atlas). Chronic
kidney disease is related to the abnormalities of lipid metabolism [22,
23]. Given that SLC17A3 is related to the alterations in serum lipid
concentration via renal regulation, the association of SLC17A3 with the
serum LDL-cholesterol concentration might be attributable to its eﬀect
on ﬂuctuations in LDL-cholesterol concentration. The nonsynonymous
nucleotide substitution in rs34902660 of SLC17A3 alters an amino acid
at position 161 (C→ A, G161V), according to PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/index.shtml) [24] prediction (Poly-
Phen score= 0.99), may have deleterious eﬀects on the protein func-
tion. This nonsynonymous substitution also results in an amino acid
change at position 239 of an SLC17A3 splice variant (G239 V). Ac-
cording to the SIFT (http://sift.jcvi.org/) [25] prediction, the amino
acid substitution may cause a dysfunctional transcript from the splice
variant (SIFT score= 0.01). Therefore, rs34902660 of SLC17A3 could
inﬂuence serum LDL-cholesterol concentration. According to allele
frequency data from the 1000 Genomes Project, the minor allele of this
SNP is observed in Japanese and African populations.
The minor allele of rs1042127 in CDSN at 6p21.33 may be a risk
factor for the incidence of hyper-LDL-cholesterolemia. CDSN is a can-
didate susceptible locus for disorders, such as psoriasis, hypotrichosis,
and peeling skin syndrome [26–29]. A nonsynonymous nucleotide
substitution T→G at position 408 (S408A) in CDSN may cause a dys-
functional protein, as predicted by the PolyPhen-2 (score= 0.928).
Therefore, the SNP of CDSN may be important for the incidence of
hyper-LDL-cholesterolemia. CDSN protein is involved in the shedding of
superﬁcial corneocytes from facial skin. Severe psoriasis has been as-
sociated with diﬀerent disorders, including cardiovascular diseases and
type 2 diabetes mellitus [30]. Moreover, a previous study has revealed
that the mean concentrations of triglycerides, LDL-cholesterol, and total
cholesterol in patients with psoriasis were signiﬁcantly higher than
those in controls [31]. Although the relevance of the candidate SNP of
CDSN in the pathogenesis of hyper-LDL-cholesterolemia remains un-
clear, the candidate SNP in CDSN may be a risk factor for the incidence
of this disease.
There were certain limitations in the present study. First, this
longitudinal exome-wide association study was conducted in a local
Japanese population alone. Thus, the replication of longitudinal exome-
wide association studies in other Japanese populations or other ethnic
groups is warranted to verify the association of the identiﬁed SNPs with
speciﬁc diseases. Second, the functional relevance of the candidate
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Therefore, further functional analyses are required to validate the re-
sults of this study. Third, the exome-wide association study is a focus
genotyping method for whole exons and diﬀers from whole genome
sequence analyses which provide a complete coverage of coding and
non-coding variants across the entire human genome. The SNPs ex-
amined in the present study are only exonic variants.
4. Conclusion
In our longitudinal exome-wide association studies, 82 SNPs were
signiﬁcantly associated with at least one of the six dyslipidemia-related
traits (hypertriglyceridemia; hypo-HDL-cholesterolemia; hyper-LDL-
cholesterolemia; and serum concentrations of triglycerides, HDL-
cholesterol, or LDL-cholesterol). Among these, four and two SNPs were
identiﬁed as novel susceptibility loci for hypo-HDL-cholesterolemia and
hyper-LDL-cholesterolemia, respectively.
5. Materials and methods
5.1. Ethics statement
The study protocol complied with the Declaration of Helsinki and
was approved by the Committees on the Ethics of Human Research of
Mie University Graduate School of Medicine (Tsu, Mie, Japan) and
Inabe General Hospital (Inabe, Mie, Japan). Written informed consent
was obtained from all subjects prior to study enrolment in the study.
Table 4
Mean serum concentrations of HDL- or LDL-cholesterol in subjects with diﬀerent genotypes of each candidate SNP in the discovery cohort, based on measurement
data of subjects in the latest year.
RefSNP ID Locationa Gene Genotype HDL-cholesterol (mmol/L)b P-valuec LDL-cholesterol (mmol/L)b P-valuec
rs34902660 6: 25,850,874 SLC17A3 CC 1.66 ± 0.45 0.4131 3.15 ± 0.80 0.0005
CA 1.64 ± 0.46 3.25 ± 0.80
AA 1.68 ± 0.50 3.36 ± 0.84
rs1042127 6: 31,116,393 CDSN TT 1.66 ± 0.44 0.8840 3.14 ± 0.79 0.0007
TG 1.65 ± 0.45 3.21 ± 0.82
GG 1.66 ± 0.47 3.26 ± 0.79
rs74416240 12: 109,904,793 TCHP GG 1.67 ± 0.45 5.63×10−7 3.16 ± 0.80 0.4527
GA 1.63 ± 0.44 3.19 ± 0.80
AA 1.51 ± 0.37 3.21 ± 0.73
rs925368 12: 109,953,174 GIT2 AA 1.53 ± 0.37 2.46×10−6 3.21 ± 0.73 0.4513
AG 1.62 ± 0.44 3.19 ± 0.80
GG 1.67 ± 0.45 3.16 ± 0.80
rs7969300 12: 111,555,908 ATXN2 TT 1.63 ± 0.43 4.96×10−5 3.17 ± 0.77 0.9005
TC 1.66 ± 0.45 3.17 ± 0.81
CC 1.71 ± 0.48 3.18 ± 0.86
rs12231744 12: 112,039,251 NAA25 CC 1.64 ± 0.44 1.83×10−5 3.16 ± 0.78 0.3972
CT 1.66 ± 0.45 3.19 ± 0.81
TT 1.73 ± 0.48 3.15 ± 0.85
HDL, high density lipoprotein. LDL, low density lipoprotein.
a Location in NCBI build GRCh38.
b Quantitative data are means and standard deviations.
c Based on Bonferroni's correction, a P-value of< 0.008 (0.05/6) was considered statistically signiﬁcant (by one-way analysis of variance) and is shown in bold.
Table 5
Mean serum concentrations of HDL- or LDL-cholesterol in subjects with diﬀerent genotypes of each candidate SNP in the replication and entire cohorts.
RefSNP ID Locationa Gene Genotype HDL-cholesterolb P-valuec LDL-cholesterol b P-valuec
Replication Entired Replication Entired Replication Entired Replication Entired
rs34902660 6: 25,850,874 SLC17A3 CC 1.36 ± 0.44 1.48 ± 0.47 0.0003 0.4746 3.06 ± 0.89 3.10 ± 0.85 0.1349 5.90×10−5
CA 1.31 ± 0.43 1.47 ± 0.47 3.12 ± 1.00 3.19 ± 0.91
AA 1.24 ± 0.50 1.47 ± 0.54 3.23 ± 0.94 3.30 ± 0.89
rs1042127 6: 31,116,393 CDSN TT 1.36 ± 0.44 1.48 ± 0.47 0.0059 0.1543 3.06 ± 0.89 3.09 ± 0.85 0.3712 0.0008
TG 1.33 ± 0.43 1.47 ± 0.47 3.09 ± 0.94 3.15 ± 0.88
GG 1.38 ± 0.49 1.51 ± 0.50 3.10 ± 0.93 3.18 ± 0.87
rs74416240 12: 109,904,793 TCHP GG 1.37 ± 0.45 1.49 ± 0.47 1.91×10−6 2.93×10−6 3.07 ± 0.91 3.11 ± 0.86 0.6093 0.1835
GA 1.32 ± 0.42 1.46 ± 0.45 3.09 ± 0.91 3.14 ± 0.86
AA 1.25 ± 0.38 1.38 ± 0.39 3.09 ± 0.92 3.15 ± 0.82
rs925368 12: 109,953,174 GIT2 AA 1.37 ± 0.45 1.49 ± 0.47 9.85×10−6 4.35×10−5 3.07 ± 0.91 3.11 ± 0.87 0.4452 0.1502
AG 1.32 ± 0.42 1.45 ± 0.45 3.10 ± 0.92 3.14 ± 0.86
GG 1.26 ± 0.38 1.40 ± 0.40 3.04 ± 0.84 3.13 ± 0.78
rs7969300 12: 111,555,908 ATXN2 TT 1.33 ± 0.42 1.45 ± 0.45 4.13×10−7 5.25×10−9 3.12 ± 0.91 3.14 ± 0.85 0.0044 0.0249
TC 1.36 ± 0.44 1.48 ± 0.47 3.05 ± 0.91 3.10 ± 0.87
CC 1.40 ± 0.47 1.53 ± 0.50 3.03 ± 0.90 3.10 ± 0.88
rs12231744 12: 112,039,251 NAA25 CC 1.33 ± 0.43 1.45 ± 0.46 1.88×10−6 8.35×10−10 3.11 ± 0.92 3.14 ± 0.85 0.0038 0.0584
CT 1.37 ± 0.44 1.49 ± 0.47 3.04 ± 0.92 3.11 ± 0.88
TT 1.40 ± 0.46 1.54 ± 0.49 3.03 ± 0.84 3.08 ± 0.85
HDL, high density lipoprotein. LDL, low density lipoprotein.
a Location in NCBI build GRCh38.
b Quantitative data are means and standard deviations (mmol/L).
c Based on Bonferroni's correction, a P-value of< 0.008 (0.05/6) was considered statistically signiﬁcant (by one-way analysis of variance) and is shown in bold.
d Entire cohort: combined cohort of discovery and replication cohorts.
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5.2. Study subjects
In total, 6022 community-dwelling individuals were recruited from
among those who visited the Health Care Center at Inabe General
Hospital for an annual health checkup and were followed-up (discovery
cohort). All subjects had undergone 1–11 medical examinations from
April 2003 to March 2014, and the average follow-up period was
5 years. Detailed methods regarding subject recruitment and the col-
lection and storage of medical examination data and genomic DNA
samples have been previously described [32]. Cross-sectional data for
dyslipidemia-related traits in 8310 Japanese subjects (Gifu Prefectural
Tajimi Hospital, Tajimi, Japan; Gifu Prefectural General Medical
Center, Gifu, Japan; Japanese Red Cross Nagoya First Hospital, Nagoya,
Japan; and Hirosaki University Hospital and Hirosaki Stroke Center,
Hirosaki, Japan) were used for the replication studies of candidate SNPs
identiﬁed from our longitudinal exome-wide association studies. We
refer to this cohort as “replication cohort.”
Venous blood was collected in the early morning following over-
night fasting. The blood samples were centrifuged at 1600×g for
15min at 4 °C, and serum was separated for subsequent analysis.
Hypertriglyceridemia was deﬁned as either a serum triglyceride con-
centration of ≥1.69mmol/L or the current use of antidyslipidemic
medications for hypertriglyceridemia. Hypo-HDL-cholesterolemia was
deﬁned as a serum HDL-cholesterol concentration of< 1.03mmol/L.
Hyper-LDL-cholesterolemia was deﬁned as a serum LDL-cholesterol
concentration of ≥3.62mmol/L or the current treatment with anti-
dyslipidemic agents for hyper-LDL-cholesterolemia. Subjects with dys-
lipidemia presented with at least one of hypertriglyceridemia, hypo-
HDL-cholesterolemia, or hyper-LDL-cholesterolemia, or were receiving
antidyslipidemic medications.
In the longitudinal exome-wide association studies for hyper-
triglyceridemia or hypo-HDL-cholesterolemia, 6022 subjects were ex-
amined (3966 controls and 2056 subjects with hypertriglyceridemia or
5324 controls and 698 subjects with hypo-HDL-cholesterolemia, to-
taling 28,521 examinations per study). In the longitudinal exome-wide
association studies for hyper-LDL-cholesterolemia (3251 controls and
2769 subjects with hyper-LDL-cholesterolemia, totaling 28,511 ex-
aminations), 6020 subjects were examined. Of these, 540 subjects with
both hypertriglyceridemia and hypo-HDL-cholesterolemia and 3808
controls overlapped between the longitudinal exome-wide association
studies for these phenotypes. Further, 1334 subjects with both hyper-
triglyceridemia and hyper-LDL-cholesterolemia and 2530 controls as
well as 395 subjects with both hypo-HDL-cholesterolemia and hyper-
LDL-cholesterolemia and 2950 controls overlapped between the corre-
sponding studies. The numbers of serum samples examined were
28,038 (5988 subjects) for triglycerides, 28,003 (5988 subjects) for
HDL-cholesterol, and 26,831 (5987 subjects) for LDL-cholesterol. The
distribution of serum concentrations of triglycerides, HDL-cholesterol,
and LDL-cholesterol are presented in Supplementary Fig. S1.
The replication cohort comprised 2685 subjects with hyper-
triglyceridemia and 4703 controls in the cross-sectional association
study for hypertriglyceridemia; 1947 subjects with hypo-HDL-choles-
terolemia and 6146 controls in the study for hypo-HDL-cholester-
olemia; and 1719 subjects with hyper-LDL-cholesterolemia and 5833
controls in the study for hyper-LDL-cholesterolemia. Of these, 759
subjects with both hypertriglyceridemia and hypo-HDL-cholesterolemia
and 4033 controls; 667 subjects with both hypertriglyceridemia and
hyper-LDL-cholesterolemia and 3793 controls; and 316 subjects with
both hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia and
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Fig. 5. Box-plots of serum LDL- or HDL-cholesterol levels of subjects with diﬀerent genotypes of each candidate SNP in the discovery cohort. HDL, high density
lipoprotein. LDL, low density lipoprotein.
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5.3. Longitudinal exome-wide association study
A longitudinal exome-wide association study of the discovery cohort
was performed using ~244,000 genetic variants and the longitudinal
data from medical examinations. All samples in the discovery cohort
were genotyped using Inﬁnium HumanExome-12 ver 1.2 BeadChip and
Inﬁnium Exome-24 ver 1.0 BeadChip (Illumina, San Diego, CA, USA).
These arrays include putative functional exonic variants selected
from>12,000 individual exome and whole-genome sequences across
diverse ethnic populations, including European, African, Chinese, and
Hispanic individuals [33].
Quality controls for the genotyping data were performed, and
monomorphic sites and the following genetic variants were discarded:
variants contained in only one of the exome arrays used (~3.6% of all
variants), variants with a call rate of< 97.0%, variants in which the
genotype distribution signiﬁcantly deviated from the Hardy–Weinberg
equilibrium (P < .001) in controls, variants on the mitochondrial DNA
and sex chromosomes, and variants with an MAF of< 0.05.
Additionally, the gender speciﬁcation was examined for each sample,
and samples for which the gender designation in the clinical records
was inconsistent with the genetic sex were discarded. Cryptic related-
ness and duplicate samples were assessed by calculating the identity by
descent (IBD); all pairs of DNA samples indicating an IBD of> 0.1875
were inspected, and one sample from each pair was excluded. Principal
component analysis (PCA) of SNPs using the EIGENSTRAT method [34]
via JMP Genomics version 6.0 (SAS Institute, Cary, NC, USA) was
conducted to detect population stratiﬁcation on a genome-wide scale.
No population outliers were identiﬁed in PCA. Consequently, 24,691
SNPs among 6022 Japanese individuals (3788 patients with dyslipi-
demia and 2234 controls) passed the quality control for the longitudinal
studies.
Using JMP Genomics, the genotyping data of 6022 individuals were
converted into numeric data with three inheritance models (dominant,
additive, and recessive). The dominant and recessive models were de-
ﬁned as “AA (0) vs. AB+BB (1)” and “AA+AB (0) vs. BB (1)” (A,
major allele; B, minor allele), respectively, whereas the additive model
was deﬁned as “AA (0), AB (1), BB (2).” The rearrangement of the
longitudinal data was conducted using the R software version 3.4.2 (R
Foundation for Statistical Computing, Vienna, Austria) [35] via RStudio
1.1.183 [36] and Perl script.
Quantile–quantile plots for the P-values in the exome-wide asso-
ciation studies for the clinical parameters related to dyslipidemia in the
three inheritance models were performed (Supplementary Figs. S2–S4).
The genomic inﬂation factor (λ) of the P-values in the dominant, ad-
ditive, and recessive models were 1.05 for hypertriglyceridemia,
1.15–1.16 for serum triglyceride concentration, 1.00–1.09 for hypo-
HDL-cholesterolemia, 1.09 for serum HDL-cholesterol concentration,
0.98–1.05 for hyper-LDL-cholesterolemia, and 1.00–1.14 for serum
LDL-cholesterol concentration.
5.4. Statistical analyses
The association of SNPs with the six dyslipidemia phenotypes was
tested using the GEE model [37, 38] with adjustments for age, sex, BMI,
and smoking status using the R package “geepack” [39]. Since the
prevalence of hypertriglyceridemia, hypo-HDL-cholesterolemia, and
hyper-LDL-cholesterolemia was a repeated categorical data (case or
control), a binomial distribution was applied for assessing the correla-
tion between the repeated categorical outcomes and SNPs in the GEE
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Fig. 6. Box-plots of serum LDL- or HDL-cholesterol levels of subjects with diﬀerent genotypes of each candidate SNP in the replication cohort. HDL, high density
lipoprotein. LDL, low density lipoprotein.
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prevalence of hypertriglyceridemia under a ﬁrst-order autoregressive
(ar1) model for working correlation matrix (correlation of repeated
measurements within an individual) using GEE approach in the R
package “geepack” is obtained by
+ + +
+ = =
geeglm (Prevalence of hypertriglyceridemia~SNP age sex BMI
smoking status, family binomial, corstr “ar1”)
A Gaussian (normal) distribution was selected for the family with an
identity link in the GEE for serum concentrations of triglycerides, HDL-
cholesterol, and LDL-cholesterol because the repeated measurements
were continuous data. The ﬁt with the serum concentration of trigly-
ceride is obtained by
+ + +
+ = =
geeglm (Serum concentration of triglyceride~SNP age sex BMI
smoking status, family gaussian, corstr “ar1”)
Missing data of response variables or covariates were removed from
the GEE analysis. The waves argument was used to specify the ordering
of repeated measurements within individuals.
After applying Bonferroni's correction to compensate for multiple
comparisons of genotypes with the clinical parameters, the statistical
signiﬁcance of the association was P < 2.03×10−6 (0.05/24,691
SNPs) for the three inheritance models. Sitlani et al. [40] have reported
that a small eﬀective sample size could increase the probability of
generating false positives (type I errors). They have recommended the
use of approxdf, a scale of small eﬀective sample size, as follows: ap-
proxdf= 2×MAF×Nindep, where Nindep is the sum of the esti-
mated number of independent observations per subject. The study in-
dicated that an approxdf ≥10 could reduce type I errors. Thus, we
estimated the approxdf using the R package “bosswithdf” [40, 41]. To
avoid false positive association in small sample sizes, a strict approxdf
threshold was applied and SNPs with an approxdf≤30 were discarded.
5.5. LD estimates
After the SNP data were converted into suitable formats by Perl and
R scripts, LDs between pairs of SNPs were estimated using Haploview
version 4.2 [42] program. The association of candidate SNPs with
dyslipidemia-related phenotypes reported by previous studies was in-
vestigated using GRASP (https://grasp.nhlbi.nih.gov/Overview.aspx)
[43], GWAS Catalogue (https://www.ebi.ac.uk/) [44], and DisGeNET
(http://www.disgenet.org/web/DisGeNET/) [45] databases.
Information regarding the allele frequencies of target SNPs within
four ethnic populations (East Asian, South Asian, European, and
African) was obtained from the 1000 Genomes Project (http://www.
internationalgenome.org/) [46] through the Ensembl genome browser
(http://www.ensembl.org) [47]. The categories of the ethnic popula-
tions are listed at the following URL: http://www.internationalgenome.
org/data-portal/population. To survey the LDs between the candidate
SNPs detected in the present study and previously identiﬁed dyslipi-
demia-associated SNPs in JPT from the 1000 Genomes Project, analyses
using the LDproxy of LDlink (https://analysistools.nci.nih.gov/LDlink/)
[48], which is a web-based application designed to interrogate LD in
population groups, and GRASP database were conducted as follows.
First, LDs between the candidate SNP and neighboring SNPs in a spe-
ciﬁc chromosomal region were comprehensively examined using
LDproxy. Second, the association between the dyslipidemia-related
phenotypes and SNPs that were in LD with the candidate SNP
(r2 > 0.5) was investigated using GRASP database. Third, if the SNP in
LD with the candidate SNP did not exhibit a signiﬁcant association
(P > 2.03× 10−6) with the dyslipidemia-related phenotypes, the
candidate SNP was identiﬁed as a novel susceptibility locus for dysli-
pidemia.
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